Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors

Sponsor

Ann & Robert H Lurie Children's Hospital of Chicago (Other)

Overall Status

Unknown status

CT.gov ID

NCT00679536

Collaborator

(none)

Enrollment

Location

Arm

Duration (Months)

0.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The study proposes the use of Fludarabine, Busulfan, Anti Thymocyte Globulin Rabbit (ATG) and Total Body Irradiation as a preparative regimen before hematopoietic stem cell transplant from unrelated donor peripheral blood stem cells (PBSC). The hypothesis states that the 100 day mortality after this type of transplant will be significantly below the accepted standards, which is about 30% for unrelated donors.

Condition or Disease	Intervention/Treatment	Phase
Leukemia	Drug: Busulfan Drug: Fludarabine Drug: Thymoglobulin Radiation: Total Body Irradiation	Phase 1/Phase 2

Detailed Description

The primary objective of this study is to evaluate the toxicity (as measured as 100 day survival) after hematopoietic stem cell transplant from an unrelated donor with a novel preparative regimen of Fludarabine, Busulfan, Anti-Thymocyte Globulin, and Total Body Irradiation for pediatric patients with leukemia. The secondary objectives are to evaluate the relapse-free and overall survival after hematopoietic stem cell transplant as well as to evaluate the incidence of acute and chronic graft-versus-host disease after this preparative regimen.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

30 participants

Allocation:

Non-Randomized

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors Using Fludarabine, Busulfan, 400 cGy Total Body Irradiation, and Thymoglobulin

Study Start Date :

May 1, 2008

Anticipated Primary Completion Date :

May 1, 2015

Anticipated Study Completion Date :

May 1, 2015

Arms and Interventions

Arm	Intervention/Treatment
Experimental: A All patients on this trial will receive a conditioning regimen of Busulfan, Fludarabine, Anti-Thymocyte Globulin and Total Body Irradiation (400 cGy)	Drug: Busulfan Patient will receive a Test Dose of Busulfan on either Day -10 or Day -9. Patient will receive their Regimen Dose of Busulfan on Day -5 to Day -2. The regimen dose of Busulfan will be based off of the findings from their Test Dose. Other Names: IV Busulfex Drug: Fludarabine Patient will receive Fludarabine from Day -6 to Day -2. The dose of Fludarabine will be 30 mg/m^2/day. Other Names: Fludara Drug: Thymoglobulin The patient will also receive Thymoglobulin (rabbitATG) on Day -4 to Day -2. Each dose of rabbitATG will be 1.5 mg/kg/day. Radiation: Total Body Irradiation On Day -1 the patient will receive a total of 400 cGy of Total Body Irradiation.

Arm

Intervention/Treatment

Experimental: A

All patients on this trial will receive a conditioning regimen of Busulfan, Fludarabine, Anti-Thymocyte Globulin and Total Body Irradiation (400 cGy)

Drug: Busulfan

Patient will receive a Test Dose of Busulfan on either Day -10 or Day -9. Patient will receive their Regimen Dose of Busulfan on Day -5 to Day -2. The regimen dose of Busulfan will be based off of the findings from their Test Dose.

Other Names:

IV Busulfex

Drug: Fludarabine

Patient will receive Fludarabine from Day -6 to Day -2. The dose of Fludarabine will be 30 mg/m^2/day.

Other Names:

Fludara

Drug: Thymoglobulin

The patient will also receive Thymoglobulin (rabbitATG) on Day -4 to Day -2. Each dose of rabbitATG will be 1.5 mg/kg/day.

Radiation: Total Body Irradiation

On Day -1 the patient will receive a total of 400 cGy of Total Body Irradiation.

Outcome Measures

Primary Outcome Measures

To evaluate the toxicity (as measures by 100 day survival) after hematopoietic stem cell transplant from an unrelated donor with a novel preparative regimen. [100 day mortality]

Secondary Outcome Measures

To evaluate the relapse-free and overall survival after hematopoietic stem cell transplant with Fludarabine/Busulfan/ATG/TBI preparative regimen for pediatric patients with leukemia. [5 years]
To evaluate the incidence of acute and chronic graft-versus-host disease after hematopoietic stem cell transplant [5 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A to 21 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Ages 0-21
AML in one of the following stages:
Having preceding myelodysplasia (MDS)
High Risk cytogenetics
Requiring > 2 cycles chemotherapy to obtain complete remission
High allelic ratio FLT3/ITD+,
Standard risk cytogenetics with positive MRD at end of Induction
Second or greater CR
First relapse with < 25% blasts in bone marrow
With therapy-related AML whose prior malignancy has been in remission for at least 12 months
ALL in one of the following stages:
High risk first remission, defined as:
Ph+ ALL; or,
MLL rearrangement with slow early response [defined as having M2 (5-25% blasts) or M3 (>25% blasts on bone marrow examination on Day 14 of induction therapy)]; or,
Hypodiploidy (< 44 chromosomes or DNA index < 0.81); or,
End of induction M3 bone marrow; or,
End of induction M2 marrow or MRD>1% with M2-3 marrow or MRD>1% at Day 42.
High-risk infant ALL defined as age <6 months at diagnosis with MLL (11q23) translocation.
High risk second remission, defined as:
Bone marrow relapse < 36 months from induction; or >36 mths if a matched sibling donor is available
T-lineage relapse at any time; or,
Very early isolated CNS relapse (<18 months from diagnosis); or,
Slow reinduction (M2-3 at Day 28) after relapse at any time.
Any third or subsequent CR.
Biphenotypic or undifferentiated leukemia in any CR or if in first relapse must have < 25% blasts in bone marrow
MDS at any stage; prior therapies allowed
CML in chronic or accelerated phase; prior therapies allowed
Patient also must have the following organ requirements:
Adequate renal function defined as serum creatinine <2x normal, or creatinine clearance > 40 ml/min/m^2 or 70 ml/min.
Adequate liver function as defined by total bilirubin less than or equal to 2 times normal and AST and ALT less than or equal to 4 times normal.
Adequate cardiac function as defined by: shortening fraction > 24% by echocardiogram, or ejection fraction > 30% by radionuclide angiogram.
Adequate pulmonary function as defined by DLCO, FEV1/FVC > 60% by pulmonary function tests. For children who are uncooperative for PFTs and have no evidence of dyspnea at rest or exercise intolerance, pulse oximetry > 94% on room air is considered acceptable, with a normal chest xray.
Adequate venous access; a double lumen central vascular access device or its equivalent and an additional PICC line will be required for all patients.
Women of childbearing potential and sexually active males should use effective contraception while on study.

Exclusion Criteria:

Inability to give informed consent or assent
Inability to obtain a suitable donor
Patient who is HIV-positive
Patient who has active Hepatitis B
Patient who is pregnant
Patient who is otherwise considered unsuitable for transplant at the discretion of the principal investigator.